USS Investment Management Ltd Sells 1,024,400 Shares of Pfizer Inc. $PFE

Key Points

• USS Investment Management Ltd reduced its stake in Pfizer Inc. by 52.3%, selling 1,024,400 shares and ending the quarter with 934,114 shares valued at approximately $23.67 million.
• Despite this reduction, other institutional investors have increased their positions in Pfizer, with significant increases including NFJ Investment Group LLC's stake rising by 103.6%.
• Pfizer reported $14.65 billion in revenue for the last quarter, surpassing analyst expectations, alongside an earnings per share of $0.78, up from $0.60 the prior year.

USS Investment Management Ltd trimmed its position in Pfizer Inc. (NYSE:PFE - Free Report) by 52.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 934,114 shares of the biopharmaceutical company's stock after selling 1,024,400 shares during the quarter. USS Investment Management Ltd's holdings in Pfizer were worth $23,666,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of PFE. Pacer Advisors Inc. lifted its stake in shares of Pfizer by 856.8% in the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock worth $508,164,000 after buying an additional 17,957,928 shares during the last quarter. Amundi raised its stake in Pfizer by 43.4% during the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock valued at $1,265,277,000 after purchasing an additional 15,758,846 shares during the last quarter. Nuveen LLC acquired a new position in Pfizer during the 1st quarter valued at $389,861,000. Starboard Value LP acquired a new position in Pfizer during the 4th quarter valued at $407,730,000. Finally, Goldman Sachs Group Inc. raised its stake in Pfizer by 51.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company's stock valued at $670,407,000 after purchasing an additional 9,041,990 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Down 1.3%

Shares of NYSE:PFE traded down $0.33 during mid-day trading on Monday, reaching $24.55. The stock had a trading volume of 49,188,016 shares, compared to its average volume of 34,669,424. The firm has a 50 day simple moving average of $24.85 and a two-hundred day simple moving average of $24.32. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The firm has a market cap of $139.56 billion, a PE ratio of 13.06, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same period in the prior year, the business earned $0.60 EPS. Pfizer's revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer's dividend payout ratio is presently 91.49%.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Jefferies Financial Group upped their target price on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday, May 21st. Bank of America upped their target price on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Berenberg Bank lowered their price target on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. Citigroup upped their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Finally, HSBC reduced their price target on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.